secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pyxis Oncology, Inc. (PYXS)
CIK:        0001782223
Form:       8-K/A
Filed at:   2026-04-30T23:59:59+00:00
Accession:  0001193125-26-193940
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Pyxis Oncology enters CEO separation agreement: 18-mo salary, equity acceleration, board resignation
--------------------------------------------------------------------------------

- Separation Agreement with former CEO Lara Sullivan became binding April 29, 2026; she resigned from Board same day.
- Dr. Sullivan will receive current salary for 18 months and health coverage for up to 12 months.
- All unvested RSUs and stock options accelerated; option exercise period extended to December 31, 2030.
- One-year post-separation non-solicitation and mutual non-disparagement covenants apply.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1782223/000119312526193940/0001193125-26-193940-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1782223/000119312526193940/pyxs-20260206.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-193940

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer